Sakar Healthcare reports strong Q3FY26 and 9MFY26 unaudited results with 62% YoY revenue growth and 58% rise in EBITDA; PAT up strongly as the company continues oncology product and dossier expansions.
AI Assistant
Sakar Healthcare Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.